We previously found an inverse relationship between sialidase Neu1 expression and metastatic potential of murine cancer cells. To elucidate the mechanism underlying the cellular events, the human sialidase gene NEU1 was overexpressed or silenced in colon cancer HT-29 cells. When NEU1-overexpressing cells were injected transsplenically into mice, in vivo liver metastasis was significantly reduced. NEU1 suppressed cell migration, invasion and adhesion in vitro, whereas the silencing resulted in the opposite. One of the major molecular changes by NEU1 was decreased sialylation of integrin b4, assessed by PNAand MAL-II-lectin blotting of immunoprecipitates with anti-integrin b4 antibody. The desialylation was accompanied by decreased phosphorylation of the integrin followed by attenuation of focal adhesion kinase and Erk1/2 pathway. Moreover, NEU1 caused downregulation of matrix metalloproteinase-7, overexpression of which is associated with cancer metastasis. Treatment of the cells with GalNAc-a-O-benzyl, an inhibitor of O-glycosylation, showed increased PNA-positive integrin b4 with its decreased phosphorylation, indicating that sialic acid removal from the integrin O-glycans results in the decreased phosphorylation. Biotinylation and immunofluorescence staining exhibited some NEU1 molecules to be at the cell surface accessible to the integrin. These results suggest that NEU1 is important in regulation of integrin b4-mediated signaling, leading to suppression of metastasis.
Introduction
Altered sialylation is closely associated with the malignant phenotype in terms of metastatic potential and invasiveness (Dennis et al., 1999; Hakomori, 2002) . To understand the causes and consequences of such aberrant sialylation, our studies have been focused on mammalian sialidases, which regulate cell-surface sialylation by removal of sialic acids from the nonreducing terminus of glycoproteins and glycolipids. Sialidase expression levels do indeed change in response to various cellular phenomena and especially in relation to cancer phenotype (Miyagi et al., 2004 (Miyagi et al., , 2008 . Four types of mammalian sialidases have been cloned to date (designated Neu1, Neu2, Neu3 and Neu4) differing in their subcellular localizations and substrate specificities (Monti et al., 2002; Miyagi and Yamaguchi, 2007) . Although functional aspects of each individual sialidase are not fully understood, they are likely involved in modulation of cellular functions through desialylation of glycoconjugates, depending on their subcellular location and substrate specificity, as well as in catabolism of the molecules themselves.
Lysosomal sialidase, Neu1, was investigated extensively as a target gene for sialidosis, and was found to be associated with a protective protein (carboxypeptidase A) and b-galactosidase as a complex in lysosomes, and the dissociation led to sialidase inactivation (Galjart et al., 1988) . The human gene NEU1 was identified as the major histocompatibility complex-related sialidase gene, and was proposed to be located in lysosomes based on the presence of the lysosomal C-terminal targeting motif.
In addition to the glycoconjugate catabolism in lysosomes, recent reports revealed that NEU1 is involved in cellular signaling, including immune responses (Liang et al., 2006) and elastin receptor-mediated signal transduction through dynamical movement from lysosomes to cell-surface membranes (Hinek et al., 2006; Duca et al., 2007) .
We previously demonstrated that Neu1 would have an important function in glycoprotein and oligosaccharide catabolism (Miyagi and Tsuiki, 1984) and that the expression level correlates inversely with metastatic capacity in rat 3Y1 transformants (Miyagi et al., 1994) and in mouse adenocarcinoma colon 26 cells (Sawada et al., 2002) of different metastatic potentials. To investigate whether overexpression of Neu1 can reverse metastatic capacity, we next introduced the gene into B16 melanoma cells, and found that sialidase overexpression resulted in suppression of experimental pulmonary metastasis (Kato et al., 2001) . Although the target molecule for the sialidase was not specified, these results indicate that Neu1 expression level influences malignant properties including the metastatic capacity. To further elucidate the mechanism underlying the sialidase effects, our studies have been extended to examine molecular changes induced by overexpression or silencing of human NEU1 gene using colon cancer cells. Herein, we demonstrated human NEU1 to suppress cell migration, invasion, adhesion and in vivo liver metastasis, and one of the targets for NEU1 to be integrin b4, desialylation of which probably caused inhibition of the downstream signaling pathway.
Results
NEU1 suppresses transsplenic in vivo liver metastasis, and cell migration and invasion of colon cancer cells NEU1 gene was transiently or stably transfected into HT-29 cells having high metastatic capacity to the liver (Trainer et al., 1998) , and the activity level was shown in Figure 1a . The transient transfection yielded an approximately 3-fold increase in sialidase activity toward 4-methylumbelliferyl-N-acetylneuraminic acid (4MU-NeuAc) as a substrate and a further increase of more than 10-fold with cotransfection of a protective protein (carboxypeptidase A) pp11 gene, which is known to be an essential cofactor for expression of the sialidase activity through complex formation together with NEU1 and b-galactosidase in lysosomes (Galjart et al., 1988) . Two clones of NEU1/pp11 stable co-transfectants showed increased activity 5-to 6-fold. Transfection of small-interfering RNA (siRNA) for NEU1 into HT-29 cells caused the mRNA reduction by over 90% relative to that of untreated cells, showing only 15-30% sialidase activity of the control cells, but the scrambled control hardly affected (Figure 1b) . The expression of other three sialidases NEU2, NEU3 and NEU4, determined by reverse transcription (RT)-PCR as described previously (Yamaguchi et al., 2005) , was not significantly altered in these cells (data not shown). Using these cells, we investigated the NEU1 effects on in vivo metastasis and on cell migration and invasion in vitro.
To investigate the NEU1 effects on liver metastasis of human colon cancer HT-29 cells, we established transsplenic liver metastasis models by injecting the stable NEU1/pp11 cotransfectants into the spleens of nude mice. At least seven mice were employed for each transfectant. The mice injected the NEU1-overexpressing cells showed significantly decreased liver metastasis in the number of metastatic nodules as compared with the case of mock cells (Figure 2a ), indicating that NEU1
gives an influence on liver metastasis in vivo. This is consistent with our previous observations that introduction of the murine Neu1 gene into B16 melanoma cells resulted in suppression of experimental pulmonary metastasis (Kato et al., 2001) .
When the cell migration and invasion were observed in vitro, NEU1 overexpression showed significant suppression as compared with the mock-transfectants, although introduction of pp11 gene alone resulted in no suppression (left in Figure 2b ), implying that this change is attributed to NEU1 expression. The stably transfected cells showed results similar to the transient transfectants (data not shown). Another human colon cancer cell line, DLD-1, also exhibited the suppression by the transfection (right in Figure 2b ). In contrast, NEU1 knockdown brought about the opposite effects (middle in Figure 2b ). It should be noted here that cell growth was barely affected by NEU1 transfection (data not shown). These indicate that NEU1 has an inhibitory 
Decreased sialylation and phosphorylation of integrin b4
To elucidate the molecular basis of the NEU1 effects, we first measured sialic acid contents in HT-29 cells by fluorometric high-performance liquid chromatography (HPLC). Protein-bound sialic acids of the control and NEU1/p11-transfected cells were 7.53 and 3.98 nmol, whereas lipid-bound sialic acids were 2.01 and 1.97 nmol, respectively. Consistent with our previous results (Miyagi and Tsuiki, 1984) , NEU1 preferentially hydrolysed glycoproteins rather than glycolipids. When the glycolipids from these cells were compared by thin layer chromatography, there was little difference detectable between NEU1/p11-and mock-transfected cells (data not shown). We next examined qualitative changes in intracellular and cell-surface glycoproteins by flow cytometry and lectin blotting. Flow-cytometric analyses with several sialic acid-related lectins showed no significant changes by the transfection with any of the lectins tested (data not shown). To identify possible endogenous glycoprotein substrates for NEU1, altered glycosylation of glycoproteins was analysed by lectin blotting with the cell homogenates. The binding to PNA lectin recognizing Gal-GalNAc structure was significantly increased by NEU1 transfection in proportion to the activity level at a nearly 230 kDa glycoprotein band, which had an electrophoretic mobility similar to integrin b4 (left in Figure 3a ). On the other hand, other four lectins, including Ricinus communis agglutinin (RCA), Maackia amurens mutagen (MAM), Sambucus siebaldiana agglutinin (SSA) and wheat-germ agglutinin (WGA) recognizing Gal-GlcNAc, a2-3, a2-6 sialyl linkages and clustered sialooligosaccharides groups as well as terminal GlcNAc, respectively, exhibited only slight and nonreproducible changes in their binding (Supplementary Figure 1 ). To confirm whether the increased binding to PNA lectin is due to decreased sialylation, we further examined another a2-3 sialyl linkage recognizing lectin, MAL-II. A modestly stained band with a molecular mass of approximately 230 kDa, similar to that obtained with PNA lectin, was observed in the mock transfectants, whereas the staining was reduced by NEU1 transfection (right Figure 3a) . As these finding suggested that integrin b4 might be desialylated by NEU1, the following two experiments were performed: immunoprecipitation of cell lysates with anti-integrin b4 antibody followed by PNA lectin blotting, and precipitation of the lysates with biotinylated PNA and streptavidin-agarose followed by immunoblotting with anti-integrin b4 antibody. The PNA binding for immunoprecipitates with anti-integrin b4 antibody was the most increased with the highest sialidase activity (Figure 3b ), and the amount of integrin b4 trapped by PNA lectin was the larger in NEU1/pp11 cotransfectants than the mock-transfectants (Figure 3c ), and on the other hand, the PNA binding was decreased by NEU1 knockdown (Figure 3d ). In contrast, the MAL-II lectin binding for immunoprecipitates with anti-integrin b4 antibody was decreased by NEU1/pp11 transfection as expected ( Figure 3e ). Furthermore, the protein immunoprecipitated with the anti-integrin b4 antibody, which showed a significant PNA affinity, was identified as integrin b4 itself by peptide sequencing, as determined the N-terminal amino-acid sequence to be Asn-X-Cys-Lys-Lys-Ala (X, unidentified amino acid). These data together strongly suggest that at least some of the integrin b4 molecules were actually desialylated by NEU1. Flow-cytometric analysis with anti-integrin b4 antibody did not show any detectable difference in the expression of cell-surface integrin protein between the NEU1/pp11-and mock-transfected cells (Supplementary Figure 1 ). To explore how desialylation of integrin b4 by NEU1 influences the related signaling, we then evaluated the tyrosine phosphorylation level of integrin b4. In HT-29 cells cultured with 10% fetal bovine serum (FBS), the phosphorylation of integrin b4 was significantly decreased in NEU1-overexpressing cells and the level seemed to be inversely correlated with the sialidase activity (left in Figure 3f ). In contrast, the phosphorylation level was higher in NEU1 siRNA-treated cells than that of control cells (middle in Figure 3f ). In DLD-1 cells, phosphorylation of the integrin was decreased in NEU1/pp11 transfectants to an extent similar to that observed in HT-29 cells (right in Figure 3e ). These results suggest that NEU1 is involved in the regulation of integrin b4 phosphorylation probably through desialylation in colon cancer cells.
Suppression of adhesion to laminin-5 and the downstream signaling of integrin b4
Because integrin b4 is known to be involved in carcinoma migration, invasion and metastasis through signal transduction by associating with adaptor proteins, including FAK (focal adhesion kinase) and Shc (Giancotti and Ruoslahti, 1999) , we next examined cell adhesion to laminin-5, one of integrin b4 ligands. As shown in Figure 4a , cell adhesion to laminin-5 was significantly suppressed in transient NEU/pp11 transfectants compared with the control cells, and this adhesion was inhibited by addition of inhibitory antibody against either laminin-5 or integrin b4 but not with a nonspecific isotype control antibody, whereas the cell adhesion tended to increase in NEU1 silenced cells (right in Figure 4a ). These data indicate that NEU1 participates essentially in cell adhesion to laminin-5. We then explored downstream signals of integrin b4. To exclude the influence from some mediators in serum, subconfluent cells were harvested, suspended in serum-free medium and allowed to attach to laminin-5 for 15-60 min. The integrin phosphorylation was stimulated in control cells by attachment maximally at approximately 30 min but suppressed by NEU1 overexpression (Figure 4b ). The phosphorylation levels in control cells were increased on laminin-5, on bovine serum albumin (BSA), and even on culture plastic by 2.7 ± 0.3-, 1.7±0.4-, 1.5±0.5-fold, respectively, compared to cell suspension. In the downstream signals of integrin b4, FAK is a mediator of integrin signaling and is involved Regulation of cancer metastasis by sialidase NEU1 T Uemura et al in the assembly of focal adhesions in tumor cells, and Shc is known as an adaptor protein recruited with integrin b4 and is often constitutively activated in tumors. When the tyrosine phosphorylation of FAK was observed, the level was remarkably decreased in NEU1/pp11 transfectants 30 min after adhesion to laminin-5 (upper in Figure 4c ). Although the Shc phosphorylation was not significantly affected (data Immunoprecipitates with anti-integrin b4 antibody was immunoblotted with anti-phospho-tyrosine antibody (P-Tyr). Sialidase activity of the cells was similar to that described in Figure 1a and b. This experiment was repeated three times with similar results. Representative immunoblots are shown, and quantification of each level was determined as a value relative to that in mock or scrambled control transfectants. IP, immunoprecipitation; IB, immunoblotting; LB, lectin blotting.
Regulation of cancer metastasis by sialidase NEU1 T Uemura et al not shown), the extent of Shc recruitment with integrin b4 was moderately decreased in the transfectants (middle in Figure 4c ). The Erk phosphorylation, which is activated by integrin through FAK and Shc, was also decreased by NEU1 overexpression in response to adhesion to laminin-5 (lower in Figure 4c ). Similar results were obtained in the stable transfectants of HT-29 cells (data not shown).
Decreased sialylation and phosphorylation of integrin b4 by treatment with GalNAc-a-O-benzyl Integrin b4 possesses several O-glycosylation sites according to prediction of the NetOGlyc 3.1 server (Julenius et al., 2004) . To further confirm whether O-glycans of integrin b4 are desialylated by NEU1, the HT-29 cells were exposed for 5 days to 2 mM GalNAc-a-O-benzyl, which is an inhibitor for glycosylation and brings about increased Galb1-3GalNAc and decreased NeuAca2-3Galb1-3GalNAc structures (Huet et al., 1998) , yielding decreased sialylation similar to the case of NEU1-overexpressing cells. The PNA lectin affinity in HT-29 cells exposed to the inhibitor was dramatically increased at a 230 kDa protein band as observed in the transfectants (Figure 5a ). In addition, the phosphorylation level of the integrin was decreased with the inhibitor (Figure 5b) , and the treated cells showed a significant decrease in cell migration and ) of Erk after attachment to laminin-5. Sialidase activity of the cells was similar to that described in Figure 1a . This experiment was repeated using four independent batches of cell lysates, and representative immunoblots are shown. Quantitative data present as values relative to that in the mock transfectants. IP, immunoprecipitation; IB, immunoblotting.
Regulation of cancer metastasis by sialidase NEU1 T Uemura et al invasion (Figure 5c ). These findings suggest that inhibition of sialylation in O-glycans of integrin b4 decreases phosphorylation to a level similar to that seen with NEU1 overexpression and causes suppression of cell migration and invasion.
Possible evidence for cell-surface localization of some NEU1 molecules Because integrin b4 is substantially localized at the cell surface, we examined whether NEU1, a sialidase majorly localized in lysosomes, could move to cell surface accessible to the integrin. HT-29 cells were subjected to cell-surface protein biotinylation at 4 1C, and labeled proteins were collected by avidin affinity chromatography followed by immunoblotting analysis with anti-NEU1 antibody. As shown in Figure 6a , some of NEU1 molecules were found in the biotinylated fractions, where a large amount of integrin b4 was collected but not the case with caveolin-1, known as a protein associated to internal site of the plasma membrane. Exogenous NEU1 protein in the transfectants was also detected similarly in the biotinylated fractions (data not shown). NEU1 in HT-29 cells was then detected by indirect immunofluorescence staining with anti-NEU1 antibody (Figure 6c ). Consistent with these data on protein biotinylation, a significant amount of NEU1 showed a cell-surface localization in nonpermeabilized cells, although NEU1 distributed diffusely in the intracellular membranes under permeabilized conditions. These results provide a possible evidence that NEU1 is somewhat distributed in the cell surface accessible to biotin. To confirm the cell-surface localization of some NEU1 proteins, a sialidase inhibitor, 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (NeuAc2en), was added to the cell culture and the effects of this inhibitor on desialylation of the integrin were observed. In comparison with the effects after and before the administration, the exogenously added inhibitor caused a significant reduction of PNA-positive integrin b4, as assessed by the lectin affinity followed by immunoblotting with anti-integrin b4 (Figure 6b ). This may be attributed to inhibition of desialylation by NEU1 localized in cell surface, as the inhibitor effect is believed to be extracellular (Hinek et al., 2006) . From these results, NEU1 is likely partially localized at the cell surface accessible to integrin b4 under the conditions. However, it may also be possible that NEU1 would meet and desialylate the integrin inside of the cells, such as in endosomes as well as at the cell surface, because a significant amount of integrin b4 remained inside of the cells (Figure 6a ).
Downregulation of matrix metalloproteinase-7
To understand further the mechanism how reduced phosphorylation of Erk in the downstream signals of integrin b4 could be linked to suppression of cell migration, invasion and metastasis, our observations were extended to the matrix metalloproteinases (MMPs) related to the integrin b4. MMPs are a family of proteolytic enzymes that contribute to the maintenance of extracellular matrix (ECM) proteins including collagens, laminins and fibronectin. It is well established that among MMPs, membrane type-1 MMP (MT1-MMP) and MMP-7 are upregulated in several cancers and have important functions in acceleration of cancer invasion and metastasis (Shiomi and Okada, 2003) . Laminin-5, one of integrin b4 ligands, has been shown as a processing target to be cleaved in the g2 chain by MT1-MMP (Koshikawa et al, 2005) and in the b3 chain by MMP-7 (Remy et al., 2006) .
We therefore examined whether the expression of these MMPs is altered by NEU1 overexpression or 
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T Uemura et al silencing. It has been described that MT1-MMP activity could be modulated by O-glycosylation (Wu et al., 2004) and that enhancement of its movement to the cell surface might occur during the enzyme activation (Remacle et al., 2006) . The MT1-MMP-catalysed activation of matrix metalloprotease-2 was then compared between the NEU1/pp11-and mock-transfected cells by gelatin zymography, and furthermore, the amount of biotinylated MT1-MMP was observed by immunoblotting with anti-MT1-MMP antibody. As shown in Figure 7a , the activities of pro-and activeforms of MMP-2 in NEU1/pp11-transfected cells were almost similar to that of the control cells. The amount of biotinylated MT1-MMP was hardly changed, and PNAlectin staining followed by immunoprecipitation did not show any detectable difference (data not shown). When the MMP-7 activity was assayed by casein zymography, the activity in the media from the NEU1-overexpressing cells was significantly lower than that of mocktransfected cells, and in contrast, NEU1 silencing showed rather a slight increase in the activity (Figure 7b ). This activity change is probably due to the difference in the protein levels, as determined by immunoblotting with anti-MMP-7 antibody (Figure 7c ), but not due to glycosylation, because no actual glycosylation site was predicted in the sequence. Thus, NEU1 does not seem to participate in regulation of MT1-MMP activity in the cells, but influences the MMP-7 expression and subsequently cell migration, invasion and metastasis.
Discussion
Alterations in ECM components and the integrin family of receptors have been observed in various cancers. Among matrix proteins, laminins have been implicated in increase in the malignant phenotype of tumor cells. Neoexpression of laminin-5 is associated with proliferation of carcinoma cells and this element often accumulates in invading edges of carcinomas (Lohi, 2001) . Integrins a3b1 and a6b4 are cell-surface receptors acting with laminin-5. In particular, integrin b4 is essential to carcinoma migration and invasion by influences on downstream pathways including FAK and Shc. This article documents the evidence in favor of desialylation of integrin b4 by sialidase NEU1 and subsequent attenuation of downstream signaling, causing reduced cell migration, invasion and metastasis. NEU1 is a major endogenous sialidase in human cells and forms a multienzyme complex including protective protein and b-galactosidase in lysosomes. Our previous observations suggested an important regulatory function of NEU1 in expression of malignant properties, because the A sialidase inhibitor, NeuAc2en, was added to the cell culture and the effects on desialylation of the integrin were observed in NEU1/pp11-transfected cells as described in Figure 3 . Quantitative data present as values relative to that in the mock transfectants without the inhibitor.
Regulation of cancer metastasis by sialidase NEU1 T Uemura et al metastatic potential of murine colon cancer cells correlated inversely with the sialidase Neu1 level and its overexpression suppressed experimental metastasis of melanoma cells. However, the molecular mechanism remains to be elucidated. Herein, we propose that integrin b4 is one of the target molecules for NEU1 controlling the malignant properties of cancer cells. There are several reports describing altered sialylation of cell-surface molecules affecting malignant characteristics and especially elevated sialylation occurring in glycoproteins of cancer cells. Consistent with the present case, hypersialylation of integrin b1 activates integrin signaling and augment cancer cell progression, probably due to upregulation of a2-6 sialyltransferase (Seales et al., 2005) . Interestingly, in contrast to NEU1, our previous observations revealed that a ganglioside-specific sialidase NEU3 is upregulated in human cancers (Kakugawa et al., 2002; Ueno et al., 2006) and activates integrinmediated signaling through ganglioside modulation (Kato et al., 2006) . These results show that sialidases indeed alter various cellular phenomena and especially in relation to cancer phenotype. With regard to cellular site for desialylation of integrin b4, NEU1 is likely to function also at the cell surface where integrin b4 is mainly located, because the sialidase has been described to move dynamically from lysosome to cell-surface membrane during differentiation, activation and assembly of elastic fibers in monocytes, T lymphocytes and fibroblasts, respectively (Hinek et al., 2006; Liang et al., 2006; Duca et al., 2007) . In agreement with these observations, we herein presented another evidence for existence of some NEU1 molecules at the cell surface of HT-29 cancer cells by the following three methods: the protein biotinylation, indirect immunofluorescence staining and accessibility of a sialidase inhibitor to NEU1, as shown in Figure 6 . In addition, we found downregulation of MMP-7 probably through NEU1-mediated attenuation of integrin b4 signaling, which may result in processing inhibition of laminin-5 and lead to suppression of cell invasion and metastasis. MMP-7 overexpression in cancers is associated with advanced clinicopathological stages, especially with colorectal cancer liver metastasis (Zeng et al., 2002) , and MMP-7 production occurs through activation of epidermal growth factor (EGF) receptor-mediated MEK/Erk signaling pathway (Mimori et al., 2004) . In this context, this study suggests that NEU1-mediated repression of Erk subsequent to decreased integrin b4 phosphorylation presumably contributes to reduced MMP-7 expression. Although we focused on integrin b4 as one of the target glycoproteins for NEU1 because of its crucial functions in cell migration, invasion and metastasis (Giannelli et al., 2002) , other molecules cannot be ruled out as NEU1 targets, affecting dependently or independently of the integrin. Our data raise the possibility that NEU1 could be utilized as a therapeutic strategy, targeting highly sialylated glycoproteins involved in cancer metastasis and invasion.
Materials and methods

Antibodies and reagents
Antibodies were obtained from the following sources: antilaminin-5 for coating on dishes (P3E4) and for adhesion inhibition (P3H9-2) and anti-integrin b4 for immunoprecipitation (3E1) and for function-blocking (ASC-8) from Chemicon; anti-integrin b4 for immunoblotting and anti-FAK from Santa Cruz; anti-Shc and anti-phospho-tyrosine (PY20) from BD Biosciences; anti-phospho-FAK (Tyr ) and anti-Erk from Cell Signaling Technology. Anti-human sialidase NEU1 antibody was prepared by immunizing rabbits with keyhole limpet hemocyanincoupled oligopeptides corresponding to amino-acid residues 201-216 and 392-410 of human NEU1. The antibody for immunofluorescence staining was from LifeSpan BioSciences (Seattle, WA, USA). Biotinylated Arachis Hypogaea (peanut) agglutinin (PNA), SSA, MAM, WGA, and RCA were products of Honen (Tokyo, Japan). Biotinylated Maackia amurensis lectin II (MAL-II) and benzyl-2-acetamido-2-deoxy-a-D-galactopyranoside (GalNAc-a-O-benzyl) were from Vector Laboratories and streptavidin-agarose was from Sigma (St Louis, MO, USA).
Cells and DNA transfection
Human colon cancer cells, HT-29 (ATCC, Manassas, VA, USA) and DLD-1 (Health Science Bank, Osaka, Japan), and gastric cancer MKN-45 cells (Health Science Bank) were routinely maintained in RPMI-1640 medium with 10% FBS at 37 1C in 5% CO 2 . Expression vectors for NEU1 (accession number X78687), pCA-NEU1, and for protective protein (pp11) (accession number M22960), pCA-pp11, were constructed by subcloning respective cDNAs into the EcoRI site of pCAGGS vector as described previously (Kato et al., 2001) . These expression vectors were transiently introduced into HT-29 cells with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) and into DLD-1 with Effectene (Qiagen, Hilden, Germany) as per the manufacturer's instructions. To obtain stable transfectants, the vectors constructed by subcloning NEU1 and pp11 cDNAs into pcDNA3.1( þ ) (Invitrogen), respectively, were introduced into HT-29 cells and positive clones were selected under G418 (Sigma) at 600 mg/ml.
Small-interfering RNA transfection siRNA targeting NEU1 and the scrambled control were obtained from Dharmacon. The sequence for targeting NEU1 was GGUCCAAGGCUGAGAACGA (NEU1 siRNA) and that for scrambled siRNA was ACGGGGUUAA AACCGCGAG (SC). siRNAs were introduced into HT-29 cells by nucleofection with the Nucleofector System (Amaxa Biosystems), and 24 h after transfection cells were subjected to various assays. The efficacy of RNA interference was analysed by measuring mRNA level with real-time PCR as described (Yamaguchi et al., 2005) .
Sialidase activity assay
Sialidase activity was determined fluorometrically with cell homogenates, using 4MU-NeuAc (Nakarai, Kyoto, Japan) as a substrate as described previously (Sawada et al., 2002) , and protein concentration by dye-binding assay (Bio-Rad).
Determination of cellular sialic acid contents Glycolipid-bound sialic acids from 10 7 cells were determined after lipid extraction followed by acid hydrolysis, and the residues were subjected to acid hydrolysis and measured as protein-bound sialic acids. Sialic acid released was measured by HPLC (Li, 1992) .
Liver metastatic ability in vivo Spleens of 6-week-old male BALBc nu/nu athymic mice were exposed through a small left flank incision under ether anesthesia and 100 ml of cell suspension (1.0 Â 10 7 cells/ml) of stable NEU1 transfectants of HT-29 cells was injected into the spleens. Mice were killed 7 weeks after tumor injection and the metastatic nodules in their spleens were counted.
Cell growth, cell migration and invasion Cell growth rate was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay using WST-1 Cell Proliferation Assay System (Takara, Tokyo, Japan). Cellular migration and invasion were assessed using cell culture inserts (Falcon) and Biocoat Matrigel Invasion Chamber (BD Biosciences), respectively, as described previously (Kato et al, 2006) .
Cell adhesion
Trypsinized cells suspended in serum-free medium were incubated with or without inhibitory antibody to laminin-5 or to integrin b4 for 30 min at 37 1C. Triplicate aliquots of suspended cells (5 Â 10 4 cells) were seeded on laminin-5-or BSA-coated 96-well culture plate, incubated for 30 min at 37 1C. Adherent cells were measured as described previously (Kato et al, 2006) . To observe the NEU1 effects on downstream integrin b4, subconfluent cells were trypsinized, suspended in serum-free medium, allowed to attach to laminin-5 or BSA for 30 min and harvested. The laminin-5 used here was purified by incubating culture medium of MKN-45 cells as the source with anti-laminin-5 antibody (P3E4) (Xia et al., 1996; Fukushima et al., 1998) .
Immunoprecipitation immunoblotting and lectin blotting
For immunoblotting, cells were lysed in 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4), 150 mM NaCl, 1% NP-40, 2 mM EDTA, 7.5 mg/ml aprotinin, 10 mg/ ml leupeptin, 10 mM sodium fluoride, 2 mM sodium orthovanadate, 0.25% sodium deoxycholate and 2 mM phenylmethylsulphonyl fluoride (PMSF), and for lectin blotting in 50 mM Tris-HCl (pH 7.4), 1% Triton X-100, 20 mg/ml leupeptin, 4 mM sodium fluoride and 0.5 mM PMSF at 4 1C for 30 min. Lysates were separated on 8% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and subjected to immunoblotting or lectin blotting, followed with HRP-conjugated secondary antibody or ABC kit (Vector, Burlingame, CA, USA), respectively. Bound antibody and lectin were detected with ECL (Amersham) using Versa Doc imaging system (Bio-Rad). Densitometric analyses were performed with ImageJ (NIH, USA). In some experiments, lysates were immunoprecipitated by incubating with 3.5 ml of anti-integrin b4 (3E1) and protein G-Sepharose beads for 3 h at 4 1C and subjected to immunoblotting or lectin blotting. To detect some glycoproteins for PNA lectin binding, the cell extracts were incubated with 4 mg biotinylated-PNA lectin and 20 ml of streptavidin-agarose for 5 h at 4 1C and the glycoproteins collected were immunoblotted with anti-integrin b4 antibody.
Inhibition of O-glycosylation elongation by GalNAc-a-O-benzyl treatment
GalNAc-a-O-benzyl in dimethyl sulfoxide (DMSO) was added to the culture medium to give a final concentration to be 2 mM in 0.3% DMSO. The cells were incubated for 5 days at 37 1C, and the lysates were subjected to lectin blotting or immunoprecipitation followed by immunoblotting.
Biotinylation of cell-surface proteins Cells were washed three times with ice-cold PBS (pH 8.0) and incubated with 10 mg/ml membrane-impermeable sulfo-NHS-LC-Biotin (Pierce, Waltham, MA, USA) for 30 min, according to the manufacturer's instructions. Cells were then washed with 100 mM glycine/PBS to quench and remove excess biotin reagent, and treated with immunoprecipitation assay buffer. After centrifugation, biotinylated proteins were collected using streptavidin-agarose resin.
Indirect immunofluorescence microscopy HT-29 cells grown on glass coverslips were fixed for 15 min at 4 1C, treated with or without 0.2% Triton X-100 for 15 min at 37 1C and blocked with 1% BSA for 30 min at 37 1C. Detection of NEU1 was achieved using anti-NEU1 antibody and Alexa Fluor 488-conjugated anti-rabbit IgG antibody (Molecular Probes, Carlsbad, CA, USA). Preparations were mounted onto coverslips with PermaFluor (Shandon Immunon, Waltham, MA, USA) and analysed with the Zeiss-LSM confocal microscope.
Zymography analysis for MMP activity Cells were cultured with serum-free medium for 16 h, and the conditioned medium collected was mixed with SDS buffer without reducing reagent. After electrophoresis on SDS-PAGE containing gelatin at 1 mg/ml (for MMP-2) or casein at 1 mg/ml (for MMP-7), gels were washed with 2.5% Triton X-100 in Tris-HCl (pH 8.0). To activate MMPs, gels were incubated with Tris-HCl (pH 8.0) containing 0.5 mM CaCl 2 and 1 mM ZnCl 2 at 37 1C for 16 h, and then stained with 0.1% Coomassie R-250. Proteolytic activities of MMPs were evidenced as clear bands against the blue background.
